

Safety Data Sheet

acc. to OSHA HCS

Revision date 01/10/2021

1 Identification

Printing date 01/10/2021

· Product identifier

- · Trade name: IgG (rabbit) Monoclonal Antibody Biotinylated
- · Synonym Immunoglobulin G
- Article number: 32360
- · Application of the substance / the mixture For research use only, not for human or veterinary use.


· Details of the supplier of the safety data sheet

- Manufacturer/Supplier: Cayman Chemical Co. 1180 E. Ellsworth Rd. Ann Arbor, MI 48108 USA
- Information department: Product safety department
 Emergency telephone number: During normal opening times: +1 (734) 971-3335 US/CANADA: 800-424-9300 Outside US/CANADA: 703-741-5970

2 Hazard(s) identification

• **Classification of the substance or mixture** The product is not classified, according to the Globally Harmonized System (GHS).

- · Label elements
- · GHS label elements None
- · Hazard pictograms None
- · Signal word None
- · Hazard statements None
- · Classification system:
- NFPA ratings (scale 0 4)



· HMIS-ratings (scale 0 - 4)

HEALTH0Health = 0FIRE1Fire = 1REACTIVITY0Reactivity = 0

- · Other hazards
- · Results of PBT and vPvB assessment
- · PBT: Not applicable.
- **vPvB:** Not applicable.

(Contd. on page 2)

Printing date 01/10/2021

Revision date 01/10/2021

Trade name: IgG (rabbit) Monoclonal Antibody - Biotinylated

(Contd. from page 1)

-	ormation on ingredients	
•	of the substances listed below with nonhazardous additions	S
 Dangerous compone 	ents:	
CAS: 56-81-5 RTECS: MA8050000	Glycerol	50.0%
CAS: 9048-46-8 RTECS: MT6446000	Albumin, bovine	1.0%
· Other ingredients		
CAS: 7732-18-5 RTECS: ZC0110000	Water	47.919%
CAS: 7647-14-5 RTECS: VZ4725000	Sodium chloride	0.85%
CAS: 7558-79-4 RTECS: WC4500000	Sodium phosphate, Dibasic	0.106%
CAS: 26628-22-8 RTECS: VY8050000	Sodium azide	0.09%
CAS: 7778-77-0 RTECS: TC6615500	Potassium phosphate, Monobasic	0.03%
	IgG (rabbit) Monoclonal Antibody - Biotinylated	0.005%

4 First-aid measures

Description of first aid measures

- · General information: No special measures required.
- After inhalation: Supply fresh air; consult doctor in case of complaints.
- After skin contact: Generally the product does not irritate the skin.
- After eye contact: Rinse opened eye for several minutes under running water.
- After swallowing: If symptoms persist consult doctor.
- Information for doctor:

• **Most important symptoms and effects, both acute and delayed** May cause anemia, cough, CNS depression, drowsiness, headache, heart damage, lassitude (weakness, exhaustion), liver damage, narcosis, reproductive effects, teratogenic effects. No further relevant information available.

• **Indication of any immediate medical attention and special treatment needed** No further relevant information available.

5 Fire-fighting measures

- · Extinguishing media
- Suitable extinguishing agents:

Use fire fighting measures that suit the environment.

- A solid water stream may be inefficient.
- Special hazards arising from the substance or mixture No further relevant information available.
- Advice for firefighters

· Protective equipment: No special measures required.

(Contd. on page 3)

Printing date 01/10/2021

Revision date 01/10/2021

Trade name: IgG (rabbit) Monoclonal Antibody - Biotinylated

(Contd. from page 2)

6 Accidenta	6 Accidental release measures				
Environmen Dilute with p Do not allow Methods ar Absorb with Reference t See Section See Section See Section	recautions, protective equipment and emergency procedures Not requipment precautions: lenty of water. to enter sewers/ surface or ground water. In anterial for containment and cleaning up: liquid-binding material (sand, diatomite, acid binders, universal binders, sa o other sections 7 for information on safe handling. 8 for information on personal protection equipment. 13 for disposal information. Action Criteria for Chemicals				
· PAC-1:					
56-81-5	Glycerol	45 mg/m³			
26628-22-8	Sodium azide	0.026 mg/m ³			
7778-77-0	Potassium phosphate, Monobasic	9.6 mg/m³			
PAC-2:	PAC-2:				
56-81-5	Glycerol	180 mg/m ³			
26628-22-8	Sodium azide	0.29 mg/m ³			
7778-77-0	7778-77-0Potassium phosphate, Monobasic110 mg/m³				
PAC-3:					
56-81-5	Glycerol	1,100 mg/m ³			
26628-22-8	Sodium azide	5.3 mg/m³			
7778-77-0	Potassium phosphate, Monobasic	630 mg/m³			

7 Handling and storage

· Handling:

- · Precautions for safe handling No special measures required.
- · Information about protection against explosions and fires: No special measures required.
- Conditions for safe storage, including any incompatibilities Keep container tightly closed.

Store in accordance with information listed on the product insert.

- · Storage:
- Requirements to be met by storerooms and receptacles: No special requirements.
- Information about storage in one common storage facility: Not required.
- · Further information about storage conditions: None.
- Specific end use(s) No further relevant information available.

8 Exposure controls/personal protection

- Additional information about design of technical systems: No further data; see item 7.
- · Control parameters
- · Components with limit values that require monitoring at the workplace:

The following constituent is the only constituent of the product which has a PEL, TLV or other recommended exposure limit.

(Contd. on page 4)

US

- US

Safety Data Sheet acc. to OSHA HCS

Printing date 01/10/2021

Revision date 01/10/2021

Trade name: IgG (rabbit) Monoclonal Antibody - Biotinylated

At this time, the remaining constituent	(Contd. from page 3) has no known exposure limits.
56-81-5 Glycerol	
PEL Long-term value: 15* 5** mg/m ³	
mist; *total dust **respirable fract	
TLV TLV withdrawn-insufficient data h	
• Additional information: The lists that	were valid during the creation were used as basis.
 Breathing equipment: Not required. Protection of hands: The glove material has to be imperment Due to missing tests no recomment 	asures: handling chemicals should be followed. able and resistant to the product/ the substance/ the preparation. dation to the glove material can be given for the product/ the
preparation/ the chemical mixture. Selection of the glove material on co degradation • Material of gloves	onsideration of the penetration times, rates of diffusion and the
The selection of the suitable gloves do quality and varies from manufacture	bes not only depend on the material, but also on further marks of er to manufacturer. As the product is a preparation of several e material can not be calculated in advance and has therefore to
	e found out by the manufacturer of the protective gloves and has ed during refilling.
9 Physical and chemical proper	ties
 Information on basic physical and c General Information 	hemical properties
· Appearance:	
Form:	Liquid
Color:	According to product specification
· Odor: · Storage Buffer	Characteristic PBS with 50% glycerol, 1% BSA, and 0.09% sodium azide
· Odor threshold:	Not determined.
Formulation	50 µg of protein G-affinity purified monoclonal antibody
· pH-value:	Not determined.
 Change in condition Melting point/Melting range: Boiling point/Boiling range: 	Undetermined. 100 °C (212 °F)
· Flash point:	199 °C (390.2 °F)
· Flammability (solid, gaseous):	Not applicable.
· Decomposition temperature:	Not determined.
Auto igniting:	Product is not selfigniting.
Denger of evaluation:	Draduat daga not progent on explosion bezard
 Danger of explosion: 	Product does not present an explosion hazard.

Printing date 01/10/2021

Revision date 01/10/2021

Trade name: IgG (rabbit) Monoclonal Antibody - Biotinylated

	(Contd. from page
· Explosion limits: Lower: Upper:	Not determined. Not determined.
· Vapor pressure at 20 °C (68 °F):	23 hPa (17.3 mm Hg)
· Density at 20 °C (68 °F):	0.99795–1.00205 g/cm³ (8.32789–8.36211 lbs/gal)
 Bulk density: Relative density Vapor density Evaporation rate 	998–1,002 kg/m³ Not determined. Not determined. Not determined.
[·] Solubility in / Miscibility with Water:	Fully miscible.
· Partition coefficient (n-octanol/wat	er): Not determined.
[·] Viscosity: Dynamic: Kinematic:	Not determined. Not determined.
Solvent content: Organic solvents: Water: VOC content:	50.0 % 47.9 % 0.00 % 0.0 g/l / 0.00 lb/gal
Solids content:	2.1 %
• Other information	No further relevant information available.

10 Stability and reactivity

- · Reactivity No further relevant information available.
- · Chemical stability
- **Thermal decomposition / conditions to be avoided:** No decomposition if used according to specifications.
- · Possibility of hazardous reactions No dangerous reactions known.
- · Conditions to avoid No further relevant information available.
- · Incompatible materials: No further relevant information available.
- · Hazardous decomposition products: No dangerous decomposition products known.

11 Toxicological information

· Information on toxicological effects

• Acute toxicity:

· LD/LC50 valu	· LD/LC50 values that are relevant for classification:			
ATE (Acute 1	ATE (Acute Toxicity Estimate)			
Oral	LD50	50,000 mg/kg		
56-81-5 Glyc	56-81-5 Glycerol			
Oral	LD50	12,600 mg/kg (rat)		
Irritation of sk	in Irritation	500 mg/24h (rabbit)		
			(Contd. on page 6)	

US

Printing date 01/10/2021

Revision date 01/10/2021

Trade name: IgG (rabbit) Monoclonal Antibody - Biotinylated

Irritation of eyes Irritation 500 mg/24h (rabbit) Intraperitoneal LD50 4,420 mg/kg (rat) Subcutaneous LD50 100 mg/kg (rat) 9048-46-8 Alburrin, bovine Intraperitoneal TDL0 0.2 pph (mouse) 26628-22-8 Sodiur azide Intraperitoneal TDL0 0.2 pph (mouse) 26628-22-8 Sodiur azide 3 ml/kg (wmn) Intraperitoneal TDL0 27 mg/kg (rat) 20628-22-8 Sodiur azide 3 ml/kg (wmn) Intraperitoneal TDL0 27 mg/kg (rat) 2050 27 mg/kg (rat) Subcutaneous LD50 45,100 µg/kg (rat) Dermal LD50 37 mg/m³ (rat) 20 mg/kg (rabbit) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Intraperitoneal LDD0 30 mg/kg (rat) Intraperitoneal LDL0 30 mg/kg (rat) Intraperitoneal LDE0 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) 50 mg/kg (rat) Intraperitoneal IDE0 30 mg/kg (rat) Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: Subcutaneous LD50 45 mg/kg Vhen used and han	irritation at avaa	Irritation	500 mg/24h (rabbit) (Contd. from page
Subcutaneous LD50 100 mg/kg (rat) 9048-46-8 Albumin, bovine Intraperitoneal TDLO Intraperitoneal TDLO 0.2 pph (mouse) 26628-22-8 Sodium azide 27 mg/kg (rat) Oral LDO 27 mg/kg (rat) DLO 3 ml/kg (wmn) LD50 27 mg/kg (rat) Subcutaneous LD50 45,100 µg/kg (rat) Dermal LD50 20 mg/kg (rat) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Interperitoneal LDLO 30 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Data 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) P	initation of eyes		
9048-46-8 Albumin, bovine Intraperitoneal TDLO 0.2 pph (mouse) 26628-22-8 Sodium azide 0ral LDLO 27 mg/kg (rat) 0ral LDLO 3 ml/kg (wmn) 1050 27 mg/kg (rat) Subcutaneous LD50 45,100 µg/kg (rat) 20 mg/kg (rat) 20 mg/kg (rat) Dermal LD50 50 mg/kg (rat) 20 mg/kg (rat) Inhalative LC50 37 mg/m³ (rat) 20 mg/kg (rat) Interperitoneal LDLO 30 mg/kg (rat) 100 µg/kg (rat) Interperitoneal LDLO 30 mg/kg (rat) 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) 28 mg/kg (mouse) Subcutaneous LD50 28 mg/kg (mouse) 28 mg/kg (mouse) Primary irritant effect: 0 nat 5,500 mg/kg (mouse) Primary irritant effect: 0 nat 5,500 mg/kg (mouse) Preparation: No irritating effect. Sensitization: No sensitizing effect known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods to preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. <t< td=""><td></td><td>•</td><td></td></t<>		•	
Intraperitoneal TDLO 0.2 pph (mouse) 26628-22-8 Sodium azide Oral LDLO 27 mg/kg (rat) TDLO 3 ml/kg (wmn) LD50 27 mg/kg (rat) Subcutaneous LD50 45,100 µg/kg (rat) Dermal LD50 20 mg/kg (rabbit) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Interperitoneal LDLO 30 mg/kg (rat) Intraperitoneal LDS0 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: on the eye: No irritant effect. on the eye: No irritant effect: specification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is	0040 40 0 0 0		100 mg/kg (rat)
26628-22-8 Sodium azide Oral LDLO 27 mg/kg (rat) TDLO 3 ml/kg (wmn) LD50 27 mg/kg (rat) Subcutaneous LD50 45,100 µg/kg (rat) Dermal LD50 50 mg/kg (rat) Inhalative LC50 37 mg/m² (rat) Subcutaneous LD50 45,100 µg/kg (rat) Inhalative LC50 37 mg/m² (rat) Subcutaneous LD50 45,100 µg/kg (rat) Interperitoneal LDLO 30 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Primary irritant effect: on the skin: No irritant effect. on the skin: No irritant effect. s,500 mg/kg (mouse) Primary irritant effect: on the eye: No irritating effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer)	9048-46-8 Albur	•	
Oral LDLO 27 mg/kg (rat) TDLO 3 ml/kg (wmn) LD50 27 mg/kg (rat) Subcutaneous LD50 45,100 µg/kg (rat) Dermal LD50 50 mg/kg (rat) Dermal LD50 50 mg/kg (rat) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Interperitoneal LDLO 30 mg/kg (rat) Intraperitoneal LDL0 30 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45,000 µg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45,000 mg/kg (mouse) Primary irritant effect: on g/kg (rat) on the skin: No irritatin effect. Sensitizing effect. Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is list	00000 00 0 0 0 1	•	0.2 ppn (mouse)
TDLO 3 ml/kg (wmn) LD50 27 mg/kg (rat) Subcutaneous LD50 45,100 µg/kg (rat) Dermal LD50 50 mg/kg (rat) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Intraperitoneal LDL0 30 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) On the skin: No irritant effect. 5,500 mg/kg (mouse) Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed.			27 mailing (rot)
LD5027 mg/kg (rat)DermalLD5045,100 µg/kg (rat)LD5050 mg/kg (rat)20 mg/kg (rabbit)InhalativeLC5037 mg/m³ (rat)Subcutaneous LD5045,100 µg/kg (rat)Interperitoneal LDLO30 mg/kg (rat)Intraperitoneal LD5028 mg/kg (mouse)Subcutaneous LD5045 mg/kg (rat)Data5,500 mg/kg (rat)On the skin: No irritant effect.on the skin: No irritant effect.on the skin: No irritant effect.Sensitization: No sensitizing effects known.Additional toxicological information:The product is not subject to classification according to internally approved calculation methods for preparations:When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us.Carcinogenic categoriesIARC (International Agency for Research on Cancer)None of the ingredients is listed.NTP (National Toxicology Program)None of the ingredients is listed.OSHA-Ca (Occupational Safety & Health Administration)	Orai		
Subcutaneous LD50 45,100 µg/kg (rat) Dermal LD50 50 mg/kg (rat) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Interperitoneal LDL0 30 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: on the skin: No irritating effect. Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administ			
Dermal LD50 50 mg/kg (rat) Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Interperitoneal LDLO 30 mg/kg (rat) Interperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) On the skin: No irritant effect. 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) Primary irritating effect. Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods foreparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration) <td></td> <td></td> <td></td>			
Inhalative LC50 37 mg/m ³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Interperitoneal LDLO 30 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) on the skin: No irritant effect. 5,500 mg/kg (mouse) Primary irritating effect. 5,500 mg/kg (mouse) Additional toxicological information: The product is not subject to classification according to internally approved calculation methods foreparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. None of the ingredients is listed. MTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)			
Inhalative LC50 37 mg/m³ (rat) Subcutaneous LD50 45,100 µg/kg (rat) Interperitoneal LDL0 30 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) on the skin: No irritant effect. 5,500 mg/kg (mouse) Additional toxicological information: Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: Specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. Subsectional Safety & Health Administration)	Dermal	LD50	
Subcutaneous LD50 45,100 µg/kg (rat) Interperitoneal LDL0 30 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) on the skin: No irritant effect. 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) on the skin: No irritant effect. 5,500 mg/kg (mouse) Additional toxicological information:			
Interperitoneal LDLO 30 mg/kg (rat) Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) on the skin: No irritant effect. 5,500 mg/kg (mouse) Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)	Inhalative		
Intraperitoneal LD50 28 mg/kg (mouse) Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) on the skin: No irritant effect. 5,500 mg/kg (mouse) Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)			
Subcutaneous LD50 45 mg/kg (rat) Data 5,500 mg/kg (mouse) Primary irritant effect: 5,500 mg/kg (mouse) on the skin: No irritant effect. 5,500 mg/kg (mouse) Sensitization: No irritant effect. 5,500 mg/kg (mouse) Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)			
Data 5,500 mg/kg (mouse) Primary irritant effect: on the skin: No irritant effect. on the skin: No irritating effect. Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)			
Primary irritant effect: on the skin: No irritant effect. on the eye: No irritating effect. Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)		Subcutaneous LD50	45 mg/kg (rat)
on the skin: No irritant effect. on the eye: No irritating effect. Sensitization: No sensitizing effects known. Additional toxicological information: The product is not subject to classification according to internally approved calculation methods for preparations: When used and handled according to specifications, the product does not have any harmful effect according to our experience and the information provided to us. Carcinogenic categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)		Data	5,500 mg/kg (mouse)
IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)	on the eye: No i Sensitization: N Additional toxic The product is r preparations: When used and	irritating effect. No sensitizing effects ki cological information not subject to classific I handled according to	: cation according to internally approved calculation methods for o specifications, the product does not have any harmful effec
None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)	Carainagania a	ategories	
NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)	Carcinogenic C		
None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration)	•	onal Agency for Rese	arch on Cancer)
OSHA-Ca (Occupational Safety & Health Administration)	IARC (Internatio		arch on Cancer)
	IARC (Internation	edients is listed.	arch on Cancer)
None of the ingredients is listed.	IARC (Internation None of the ingre- NTP (National T	edients is listed.	arch on Cancer)
	IARC (Internation None of the ingree NTP (National T None of the ingree OSHA-Ca (Occu	edients is listed. Toxicology Program) edients is listed. upational Safety & He	
	IARC (Internation None of the ingree NTP (National T None of the ingree OSHA-Ca (Occu	edients is listed. Toxicology Program) edients is listed. upational Safety & He	

· Toxicity

• Aquatic toxicity: No further relevant information available.

- Persistence and degradability No further relevant information available.
- Behavior in environmental systems:
- · Bioaccumulative potential No further relevant information available.
- Mobility in soil No further relevant information available.
- · Additional ecological information:

· General notes:

Water hazard class 1 (Self-assessment): slightly hazardous for water

(Contd. on page 7)

Printing date 01/10/2021

Revision date 01/10/2021

Trade name: IgG (rabbit) Monoclonal Antibody - Biotinylated

(Contd. from page 6) Do not allow undiluted product or large quantities of it to reach ground water, water course or sewage system.

· Results of PBT and vPvB assessment

• **PBT:** Not applicable.

· vPvB: Not applicable.

• Other adverse effects No further relevant information available.

13 Disposal considerations

· Waste treatment methods

· Recommendation: Smaller quantities can be disposed of with household waste.

· Uncleaned packagings:

• Recommendation: Disposal must be made according to official regulations.

• **Recommended cleansing agent:** Water, if necessary with cleansing agents.

· UN-Number	
DOT, IMDG, IATA	not regulated
· UN proper shipping name	
· DOT, IMDG, IATA	not regulated
· Transport hazard class(es)	
· DOT, ADN, IMDG, IATA	
· Class	not regulated
· Packing group	
DOT, IMDG, IATA	not regulated
· Environmental hazards:	Not applicable.
· Special precautions for user	Not applicable.
· Transport in bulk according to Annex	ll of
MARPOL73/78 and the IBC Code	Not applicable.
UN "Model Regulation":	not regulated

15 Regulatory information

• Safety, health and environmental regulations/legislation specific for the substance or mixture No further relevant information available.

· Sara

· Section 355 (extremely hazardous substances):

26628-22-8 Sodium azide

Section 313 (Specific toxic chemical listings):

26628-22-8 Sodium azide

• TSCA (Toxic Substances Control Act):

56-81-5 Glycerol

ACTIVE (Contd. on page 8)

Printing date 01/10/2021

Revision date 01/10/2021

Trade name: IgG (rabbit) Monoclonal Antibody - Biotinylated

		(Contd. from page 7)
7732-18-5	Water	ACTIVE
9048-46-8	Albumin, bovine	ACTIVE
	Sodium chloride	ACTIVE
	Sodium phosphate, Dibasic	ACTIVE
	Sodium azide	ACTIVE
7778-77-0	Potassium phosphate, Monobasic	ACTIVE
Hazardous	Air Pollutants	
	ingredients is listed.	
· Propositio		
	known to cause cancer:	
None of the	ingredients is listed.	
· Chemicals	known to cause reproductive toxicity for females:	
None of the	ingredients is listed.	
· Chemicals	known to cause reproductive toxicity for males:	
None of the	ingredients is listed.	
· Chemicals	known to cause developmental toxicity:	
None of the	ingredients is listed.	
· Carcinoger	nic categories	
· EPA (Envir	onmental Protection Agency)	
None of the	ingredients is listed.	
· TLV (Thres	hold Limit Value established by ACGIH)	
26628-22-8	Sodium azide	A4
· NIOSH-Ca	(National Institute for Occupational Safety and Health)	

None of the ingredients is listed.

· Chemical safety assessment: A Chemical Safety Assessment has not been carried out.

16 Other information

This information is based on our present knowledge. However, this shall not constitute a guarantee for any specific product features and shall not establish a legally valid contractual relationship.

- · Department issuing SDS: Environment protection department.
- Contact: -
- · Date of preparation / last revision 01/10/2021 / -
- Abbreviations and acronyms: IMDG: International Maritime Code for Dangerous Goods DOT: US Department of Transportation IATA: International Air Transport Association ACGIH: American Conference of Governmental Industrial Hygienists EINECS: European Inventory of Existing Commercial Chemical Substances ELINCS: European List of Notified Chemical Substances CAS: Chemical Abstracts Service (division of the American Chemical Society) NFPA: National Fire Protection Association (USA) HMIS: Hazardous Materials Identification System (USA) VOC: Volatile Organic Compounds (USA, EU) LC50: Lethal concentration, 50 percent LD50: Lethal dose, 50 percent PBT: Persistent, Bioaccumulative and Toxic vPvB: very Persistent and very Bioaccumulative NIOSH: National Institute for Occupational Safety OSHA: Occupational Safety & Health

(Contd. on page 9)

US

Printing date 01/10/2021

Revision date 01/10/2021

Trade name: IgG (rabbit) Monoclonal Antibody - Biotinylated

TLV: Threshold Limit Value PEL: Permissible Exposure Limit

REL: Recommended Exposure Limit

* Data compared to the previous version altered.

(Contd. from page 8)

US